TSX: ACB
EDMONTON, Oct. 9, 2018 /PRNewswire/ - Aurora Cannabis
Inc. ("Aurora" or the "Company") (TSX: ACB) (OTCQX: ACBFF)
(Frankfurt: 21P; WKN: A1C4WM),
announced today that the Company has filed an application to list
its common shares on the New York Stock Exchange ("NYSE").
Listing of the Company's common shares on the NYSE remains
subject to the approval of the NYSE and the satisfaction of all
applicable listing and regulatory requirements. Aurora anticipates
that, subject to receipt of all required approvals, trading in its
common shares on the NYSE will commence before the end of
October 2018. In advance of the
intended listing, the Company has filed a Form 40-F Registration
Statement with the United States Securities and Exchange
Commission.
Aurora's shares will trade on the NYSE under ticker symbol
"ACB", the same symbol the Company's common shares currently, and
will continue to, trade under on the Toronto Stock Exchange (TSX).
Aurora will also continue to trade on the OTCQX under the ticker
symbol "ACBFF" until completion of the NYSE listing. Upon receipt
of all required approvals and completion of the formal listing
process, the Company will publicly announce its first trading date
on the NYSE. Aurora furthermore intends to voluntarily delist its
shares from the OTCQX at such time.
"Through our NYSE listing, Aurora joins an established group of
mature global brands with improved access and exposure to an
engaged international institutional investor audience," said
Terry Booth, CEO of Aurora.
"Aurora's high-paced execution has made it one of the world's
leading cannabis companies. We have grown from being a licensed
producer with a single facility, to a horizontality differentiated
and vertically integrated global organization with a funded
production capacity in excess of 500,000 kg a year, sales and
operations on five continents, and a team of more than 1,500
employees."
Mr. Booth added: "Our purpose-built, indoor grow facilities,
designed to meet the stringent requirements for furnishing product
to international markets, have made Aurora the largest supplier of
medical cannabis in Europe. We are
also well-prepared for the launch of the domestic adult consumer
use market in Canada with a
portfolio of strong consumer brands and coast-to-coast provincial
supply arrangements covering 98% of the Canadian population. I am
proud of our achievements to date, and look forward to updating the
investor community as we continue to execute on our aggressive
growth strategy."
About Aurora
Headquartered in Edmonton, Alberta,
Canada with funded capacity in excess of 500,000 kg per
annum and sales and operations in 18 countries across five
continents, Aurora is one of the world's largest and leading
cannabis companies. Aurora is vertically integrated and
horizontally diversified across every key segment of the value
chain, from facility engineering and design to cannabis breeding
and genetics research, cannabis and hemp production, derivatives,
high value-add product development, home cultivation, wholesale and
retail distribution.
Highly differentiated from its peers, Aurora has established a
uniquely advanced, consistent and efficient production strategy,
based on purpose-built facilities that integrate leading-edge
technologies across all processes, defined by extensive automation
and customization, resulting in the massive scale production of
high quality product at ultra-low costs. Intended to be replicable
and scalable globally, these production facilities are designed to
produce cannabis of significant scale, with high quality,
industry-leading yields, and ultra-low per gram production costs.
Each of Aurora's facilities is built to meet EU GMP standards, and
its first production facility, the recently acquired MedReleaf
Markham facility, and its wholly owned European medical cannabis
distributor Aurora Deutschland (formerly Pedanios), have achieved
this level of certification.
In addition to the Company's rapid organic growth and strong
execution on strategic M&A, which to date includes 15 companies
– MedReleaf, CanvasRX, Peloton Pharmaceutical, Aurora
Deutschland (formerly Pedanios), H2 Biopharma, Urban Cultivator, BC
Northern Lights, Larssen Greenhouses, CanniMed Therapeutics,
Anandia Labs, HotHouse Consulting, Agropro, Borela, and the pending
acquisition of ICC Labs – Aurora is distinguished by its reputation
as a partner and employer of choice in the global cannabis sector,
having invested in and established strategic partnerships with a
range of leading innovators, including: The Green Organic Dutchman
Holdings Ltd. (TSX: TGOD), Radient Technologies Inc. (TSXV: RTI),
Hempco Food and Fiber Inc. (TSXV: HEMP), Cann Group Ltd. (ASX:
CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings
Inc. (CSE: CHOO), Namaste Technologies Inc. (TSXV: N), Evio Beauty
Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC:
CTTH), and Alcanna Inc. (TSX: CLIQ).
Aurora's Common Shares trade on the TSX under the symbol "ACB",
and are a constituent of the S&P/TSX Composite Index.
For more information about Aurora, please visit our investor
website, investor.auroramj.com, Twitter, Facebook or Instagram
Terry Booth, CEO
Aurora Cannabis Inc.
Forward looking statements
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable
securities law ("forward-looking statements"). Forward-looking
statements are frequently characterized by words such as "plan",
"continue", "expect", "project", "intend", "believe", "anticipate",
"estimate", "may", "will", "potential", "proposed" and other
similar words, or statements that certain events or conditions
"may" or "will" occur and include, but are not limited to the
variety of cannabis products that Aurora will supply to the adult
use market. These statements are only predictions. Various
assumptions were used in drawing the conclusions or making the
projections contained in the forward-looking statements throughout
this news release. Forward-looking statements are based on the
opinions and estimates of management at the date the statements are
made, and are subject to a variety of risks and uncertainties and
other factors that could cause actual events or results to differ
materially from those projected in the forward-looking statements.
The Company is under no obligation, and expressly disclaims any
intention or obligation, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as expressly required by applicable law.
Neither TSX nor its Regulation Services Provider (as that term
is defined in the policies of Toronto Stock Exchange) accepts
responsibility for the adequacy or accuracy of this release.
View original
content:http://www.prnewswire.com/news-releases/aurora-cannabis-announces-application-to-list-on-the-nyse-300727454.html
SOURCE Aurora Cannabis Inc.